(Q37972333)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

Donald R. VanDevanter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Alan R. Smyth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

David Lo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Patrick Flume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

105 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

S9-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Cystic fibrosis mortality and survival in the UK: 1947-2003

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Prediction of Mortality in Patients with Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Adherence with tobramycin inhaled solution and health care utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Microbiological and immunologic considerations with aerosolized drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970022-1

7 January 2021

10.1016/S0954-6111(11)70022-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208548%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference